Institution
Incyte
Company•Wilmington, Delaware, United States•
About: Incyte is a company organization based out in Wilmington, Delaware, United States. It is known for research contribution in the topics: Expression vector & Ruxolitinib. The organization has 1262 authors who have published 1875 publications receiving 75015 citations. The organization is also known as: Incyte Corporation & Incyte Inc..
Topics: Expression vector, Ruxolitinib, Cancer, Polynucleotide, Antibody
Papers published on a yearly basis
Papers
More filters
TL;DR: Expressed sequence tags (ESTs) are at the forefront of technological change that is sweeping the biomedical research community as mentioned in this paper and provide a high throughput means for identifying gene transcripts and monitoring complex gene expression patterns.
29 citations
Patent•
08 Jan 200229 citations
Patent•
01 Apr 2013TL;DR: In this article, a bicyclic azaheterocyclobenzylamines of Formula (I) were defined that modulate the activity of phosphoinositide 3-kinases (PI3Ks) and are useful in the treatment of diseases related to the activity, including inflammatory disorders, immune-based disorders, cancer, and other diseases.
Abstract: The present invention provides bicyclic azaheterocyclobenzylamines of Formula (I): wherein the variables are defined herein, that modulate the activity of phosphoinositide 3-kinases (PI3Ks) and are useful in the treatment of diseases related to the activity of PI3Ks including, for example, inflammatory disorders, immune-based disorders, cancer, and other diseases.
29 citations
Patent•
23 Mar 2012TL;DR: In this article, the pyrimidine-4,6-diamine derivatives of Formula (I) were used for the treatment of diseases related to the activity of PI3Ks including inflammatory disorders, immune-based disorders, cancer, and other diseases.
Abstract: The present invention provides pyrimidine-4,6-diamine derivatives of Formula (I): wherein the variables are defined herein, that modulate the activity of phosphoinositide 3-kinases (PI3Ks) and are useful in the treatment of diseases related to the activity of PI3Ks including, for example, inflammatory disorders, immune-based disorders, cancer, and other diseases.
28 citations
TL;DR: Several compounds were identified that possess excellent pharmacodynamic and pharmacokinetic properties and were shown to decrease tumor size, cleaved Her-2 extracellular domain plasma levels, and potentiate the effects of the humanized anti-HER-2 monoclonal antibody in vivo in a HER-2 overexpressing cancer murine xenograft model.
Abstract: The design, synthesis, evaluation, and identification of a novel class of (6S,7S)-N-hydroxy-6-carboxamide-5-azaspiro[2.5]octane-7-carboxamides as the first potent and selective inhibitors of human epidermal growth factor receptor-2 (HER-2) sheddase is described. Several compounds were identified that possess excellent pharmacodynamic and pharmacokinetic properties and were shown to decrease tumor size, cleaved HER-2 extracellular domain plasma levels, and potentiate the effects of the humanized anti-HER-2 monoclonal antibody (trastuzumab) in vivo in a HER-2 overexpressing cancer murine xenograft model.
28 citations
Authors
Showing all 1267 results
| Name | H-index | Papers | Citations |
|---|---|---|---|
| Patrick O. Brown | 183 | 755 | 200985 |
| David Botstein | 165 | 468 | 212787 |
| Inês Barroso | 113 | 301 | 76241 |
| Alessandro M. Vannucchi | 94 | 715 | 35482 |
| Ana M. Valdes | 84 | 334 | 26627 |
| Mark C. Genovese | 79 | 364 | 26945 |
| Michael B. Eisen | 71 | 170 | 89150 |
| Jingyue Ju | 61 | 169 | 18952 |
| Jeanne F. Loring | 60 | 177 | 14503 |
| James Z. Wang | 57 | 225 | 21890 |
| Emmett V. Schmidt | 50 | 150 | 9304 |
| Günther Sperk | 50 | 124 | 10246 |
| Robert C. Newton | 44 | 111 | 7369 |
| Magnus Pfahl | 44 | 87 | 8064 |
| William V. Williams | 44 | 168 | 7278 |